| Literature DB >> 24527038 |
Agata Sobczyńska-Malefora1, Dominic J Harrington1, Kieran Voong1, Martin J Shearer1.
Abstract
5-Methyltetrahydrofolate (5-MTHF) is the predominant form of folate and a strong determinant of homocysteine concentrations. There is evidence that suboptimal 5-MTHF availability is a risk factor for cardiovascular disease independent of homocysteine. The analysis of folates remains challenging and is almost exclusively limited to the reporting of "total" folate rather than individual molecular forms. The purpose of this study was to establish the reference intervals of 5-MTHF in plasma and red cells of healthy adults who had been prescreened to exclude biochemical evidence of functional deficiency of folate and/or vitamin B12. Functional folate and vitamin B12 status was assessed by respective plasma measurements of homocysteine and methylmalonic acid in 144 healthy volunteers, aged 19-64 years. After the exclusion of 10 individuals, values for 134 subjects were used to establish the upper reference limits for homocysteine (13 μ mol/L females and 15 μ mol/L males) and methylmalonic acid (430 nmol/L). Subjects with values below these cutoffs were designated as folate and vitamin B12 replete and their plasma and red cell 5-MTHF reference intervals determined, N = 126: 6.6-39.9 nmol/L and 223-1041 nmol/L, respectively. The application of these intervals will assist in the evaluation of folate status and facilitate studies to evaluate the relationship of 5-MTHF to disease.Entities:
Year: 2014 PMID: 24527038 PMCID: PMC3914575 DOI: 10.1155/2014/465623
Source DB: PubMed Journal: Adv Hematol
Figure 1Homocysteine, folate, and vitamin B12 metabolism. THF (tetrahydrofolate), 5-MTHF (5-methyltetrahydrofolate), MTHFR (methylene tetrahydrofolate reductase), MS (methionine synthase), CBS (cystathionine beta-synthase), SAM (S-adenosyl methionine), Cbl (cobalamin), TC II (transcobalamin), holo TC (holotrascobalamin), OH-Cbl (hydroxocobalamin), MMA-CoA (methylmalonyl-CoA), and MMA (methylmalonic acid).
Summary of results of N = 126 subjects used to derive 5-MTHF reference intervals.
| Females | Males | Student's | All | |
|---|---|---|---|---|
| Age (range) | 38 (10); 38 (23–60) | 38 (12); 36 (19–64) | 0.730 | 38 (11); 37 |
| tHcy ( | 8.4 (1.8); 7.9 | 9.7 (2.1); 9.7 | <0.001 | 8.9 (2.1); 8.9 |
| MMA (nmol/L) | 116 (93); 101 | 112 (76); 100 | 0.794 | 114 (85); 100 |
| Plasma 5-MTHF (nmol/L) | 19.4 (8.5); 19.1 | 18.7 (8.2); 17.8 | 0.624 | 19.1 (8.3); 18.2 |
| Redcell 5-MTHF (nmol/L)* | 583 (222); 572 | 585 (164); 557 | 0.975 | 586 (197); 560 |
| Whole blood 5-MTHF (nmol/L) | 618 (229); 592 | 611 (172); 582 | 0.838 | 615 (205); 584 |
*Result adjusted for plasma 5-MTHF content.
Reference intervals for 5-MTHF with 90% confidence intervals for lower and upper 95% reference limits.
| Analyte | Reference intervals | Lower reference limit | Upper reference limit |
|---|---|---|---|
| Plasma 5-MTHF (nmol/L) | 6.6–39.9 | 5.3–8.9 | 36.9–41.7 |
| Redcell 5-MTHF (nmol/L) | 223–1040 | 206–291 | 930–1110 |
| Whole blood 5-MTHF (nmol/L) | 245–1102 | 224–311 | 969–1184 |
Figure 2Distribution of the 5-MTHF concentrations in plasma and red cells.